How to prove the concerned price if the specialty is not yet produced? What is the value of a proven pricing structure if the price is downsized over time? Lets discuss to overcome this bottleneck.
You dive into a simulation model and at first everything seems flawless. But with each adjustment the risk of flaws creeping into the programming.
The 'ICER' is a well-known measure to assess the extra cost to invest to win one QALY. In Belgium, unofficially 35 000 € / QALY gained is often applied as benchmark, the 'willingness to pay' (WTP). But does the payer invest the budget in function of the potential medical need or not ?
How to prove the ‘added value’ when the concerned innovation is beneficial without producing ‘health’ in a direct way?
